Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea) (1) ·
Ceftin (oral), Zinacef (IV) (1) ·
Cipro, Cipro XR, Ciloxan (ophthalmic) (1) ·
Colace (sodium), Surfak (calcium); many generics OTC (1) ·
Dulcolax, Correctol, Bisac-Evac (1) ·
Flagyl, Metrocream, Metrogel, Metrogel-Vaginal, Noritate (1) ·
Generic; huge OTC presence (1) ·
Imodium, Imodium A-D (1) ·
Kristalose, Constulose, Generlac, Enulose (1) ·
MiraLAX (OTC), GlycoLax, GoLYTELY (with electrolytes for bowel prep), CoLyte, MoviPrep, NuLYTELY (1) ·
Mucinex, Robitussin, Tussin (1) ·
Zaditor, Alaway (ophthalmic, OTC); Zaditen (systemic, outside US) (1)
gut-restricted)]] (1) ·
[[:Category:Alpha-2_agonists|Alpha-2 adrenergic agonist]] (1) ·
[[:Category:Antibacterials|Antibacterial (anaerobic)]] (1) ·
[[:Category:Antibacterials|Antibacterial]] (1) ·
[[:Category:Antidiarrheals|Antidiarrheal]] (1) ·
[[:Category:Antioxidants|Antioxidant]] (1) ·
[[:Category:Antiprotozoals|Antiprotozoal]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) ·
[[:Category:Bowel_preparation_agents|Bowel preparation agent]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (second-generation)]] (1) ·
[[:Category:Diphenylmethane_laxatives|Diphenylmethane laxative]] (1) ·
[[:Category:Disaccharides|Non-absorbable disaccharide]] (1) ·
[[:Category:Expectorants|Expectorant]] (1) ·
[[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (1) ·
[[:Category:Glaucoma_medications|Glaucoma medication]] (1) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (1) ·
[[:Category:Hepatic_encephalopathy_treatments|Hepatic encephalopathy treatment]] (1) ·
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (1) ·
[[:Category:Mucolytics|Mucolytic]] (1) ·
[[:Category:Nitroimidazoles|Nitroimidazole antibiotic]] (1) ·
[[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (1) ·
[[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]] (1) ·
[[:Category:Opioid_receptor_agonists|Peripheral opioid receptor agonist (μ-selective (1) ·
[[:Category:Osmotic_laxatives|Osmotic laxative]] (2) ·
[[:Category:Stimulant_laxatives|Stimulant laxative]] (1) ·
[[:Category:Stool_softeners|Stool softener]] (1) ·
[[:Category:Surfactants|Surfactant]] (1) ·
[[:Category:Vitamins|Vitamin]] (1) ·
[[:Category:Water-soluble_vitamins|Water-soluble vitamin]] (1)
None (8) ·
'"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1) ·
'"`UNIQ--vote-00001067-QINU`"' Chronic use is associated with cathartic colon (colonic dilation, loss of haustration), hypokalemia, and laxative dependence; reserved for short-term use or bowel prep with breaks between courses'"`UNIQ--ref-00001068-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-0000132D-QINU`"' Electrolyte-balanced bowel-prep formulations are designed to be iso-osmotic with plasma so the volume passes through without net fluid or electrolyte shifts, the basis of their safety for whole-bowel evacuation. (1)
'"`UNIQ--vote-00000932-QINU`"', '"`UNIQ--vote-00000933-QINU`"', '"`UNIQ--vote-00000934-QINU`"', '"`UNIQ--vote-00000935-QINU`"', '"`UNIQ--vote-00000936-QINU`"', '"`UNIQ--vote-00000937-QINU`"' (1) ·
'"`UNIQ--vote-00000BE3-QINU`"', '"`UNIQ--vote-00000BE4-QINU`"', '"`UNIQ--vote-00000BE5-QINU`"', '"`UNIQ--vote-00000BE6-QINU`"', '"`UNIQ--vote-00000BE7-QINU`"', '"`UNIQ--vote-00000BE8-QINU`"', '"`UNIQ--vote-00000BE9-QINU`"', '"`UNIQ--vote-00000BEA-QINU`"' (1) ·
'"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1) ·
'"`UNIQ--vote-00000FCF-QINU`"', '"`UNIQ--vote-00000FD0-QINU`"', '"`UNIQ--vote-00000FD1-QINU`"' (1) ·
'"`UNIQ--vote-00000FF3-QINU`"', '"`UNIQ--vote-00000FF4-QINU`"', '"`UNIQ--vote-00000FF5-QINU`"', '"`UNIQ--vote-00000FF6-QINU`"', '"`UNIQ--vote-00000FF7-QINU`"', '"`UNIQ--vote-00000FF8-QINU`"' (1) ·
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1) ·
'"`UNIQ--vote-00001069-QINU`"', '"`UNIQ--vote-0000106A-QINU`"' (1) ·
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"' (1) ·
'"`UNIQ--vote-00001286-QINU`"' (1) ·
'"`UNIQ--vote-000012E5-QINU`"', '"`UNIQ--vote-000012E6-QINU`"', '"`UNIQ--vote-000012E7-QINU`"', '"`UNIQ--vote-000012E8-QINU`"' (1) ·
'"`UNIQ--vote-0000132E-QINU`"', '"`UNIQ--vote-0000132F-QINU`"', '"`UNIQ--vote-00001330-QINU`"' (1) ·
'"`UNIQ--vote-00001341-QINU`"', '"`UNIQ--vote-00001342-QINU`"' (1)
100-200 mg PO once or twice daily; pediatric weight-based (1) ·
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) ·
250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections (1) ·
4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower (1) ·
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses (1) ·
500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID (1) ·
500-750 mg PO BID; 400 mg IV q8-12h (1) ·
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1) ·
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure (1) ·
General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported (1) ·
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1)
0.025%, 0.035% ophthalmic solutions (1) ·
0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) (1) ·
10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) ·
100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) ·
100, 250, 500, 1000 mg tablets, chewables, gummies, effervescent; IV (specialty) (1) ·
125, 250, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g IV vials (1) ·
17 g (OTC) and 14 g (Rx) powder packets; 238, 510, 527 g bottles; PEG-electrolyte preparations 4 L (GoLYTELY, NuLYTELY) (1) ·
2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom) (1) ·
250, 500 mg tablets; 750 mg ER; 500 mg/100 mL IV; 0.75-1% topical gel/cream; 0.75% vaginal gel; suppository (1) ·
250, 500, 750 mg IR tablets; 500, 1000 mg ER tablets (XR); 250, 500 mg/5 mL oral suspension; 200, 400 mg IV; 0.3% ophthalmic solution and ointment; 0.2% otic (1) ·
5 mg enteric-coated tablets; 10 mg rectal suppositories; OTC and Rx (1) ·
50, 100, 250 mg capsules; 50 mg/5 mL syrup; OTC (1)
1 drop per eye q8-12h (1) ·
1 g/d (oral); 6 g/d (IV) (1) ·
16 mg/d (8 mg/d OTC) (1) ·
2.4 g/d (1) ·
30 mg/d for short-term use (1) ·
Indication-specific; bowel prep regimens reach 4 L cumulative (1) ·
Indication-specific; HE may require high-volume dosing (1) ·
TID per eye (1) ·
UL 2000 mg/d in adults (1) ·
~1500 mg/d (oral); 1200 mg/d (IV) (1) ·
~4 g/d (severe systemic infection) (1) ·
~500 mg/d typical (1)
1-3 days (1) ·
30 minutes (1) ·
30-60 minutes (1) ·
Constipation: 1-3 days; bowel prep: 1-3 hours after starting (1) ·
Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) ·
Days for symptom improvement in scurvy (1) ·
Hours (3) ·
IOP lowering at 1 hour; max at 2-3 hours (1) ·
PO 6-12 hours; PR 15-60 minutes (1) ·
Within minutes (1)
4 hours'"`UNIQ--ref-00000938-QINU`"' (1) ·
6-8 hours'"`UNIQ--ref-00000BEB-QINU`"' (1) ·
Not meaningfully described (1) ·
Not meaningfully described (negligible systemic absorption) (1) ·
Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) ·
Not meaningfully described — lactulose is not significantly absorbed (1) ·
Variable; effect dependent on local intestinal action rather than systemic kinetics'"`UNIQ--ref-0000106B-QINU`"' (1) ·
~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) ·
~1.5 hours'"`UNIQ--ref-00000FF9-QINU`"' (1) ·
~10-20 days (steady-state body pool); single dose plasma ~2 hours (1) ·
~3 hours'"`UNIQ--ref-000010D1-QINU`"' (1) ·
~9-14 hours'"`UNIQ--ref-00000FD2-QINU`"' (1)
<0.1% systemic absorption (PEG 3350 is too large to absorb intact) (1) ·
<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) ·
High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) ·
Local action; minimal systemic effect (1) ·
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' (1) ·
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) ·
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' (1) ·
~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"' (1) ·
~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"' (1) ·
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' (1) ·
~70-90% at typical doses; saturable at high doses (>500 mg) (1) ·
~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"' (1)
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern); use only when benefit clearly outweighs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable for short-term use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable when needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe after the first trimester; first-trimester use weighed against indication.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe due to minimal systemic absorption.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at routine doses; routinely supplemented in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 12 results in range #1 to #12.


